Group One Trading
BTAI icon

Group One Trading’s BioXcel Therapeutics BTAI Stock Holding History

Group One Trading’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,100
Closed -$4.96K – 7693
2025
Q4 		$4.96K Buy
3,100
+1,000
+48% +$2.06K ﹤0.01% 7184
2025
Q3 		$5.38K Sell
2,100
-100
-5% -$315 ﹤0.01% 7503
2025
Q2 		$3.98K Hold
2,200
– – ﹤0.01% 7187
2025
Q1 		$4.47K Buy
2,200
+1,925
+700% +$7.19K ﹤0.01% 6701
2024
Q4 		$1.65K Sell
275
-444
-62% -$3.71K ﹤0.01% 6786
2024
Q3 		$7.01K Hold
719
– – ﹤0.01% 5756
2024
Q2 		$14.7K Buy
719
+306
+74% +$10.2K ﹤0.01% 5421
2024
Q1 		$18.6K Sell
413
-143
-26% -$6.82K ﹤0.01% 5473
2023
Q4 		$26.3K Sell
556
-513
-48% -$28.5K ﹤0.01% 5536
2023
Q3 		$43.3K Sell
1,069
-2,294
-68% -$232K ﹤0.01% 5238
2023
Q2 		$358K Buy
3,363
+3,082
+1,097% +$1.03M ﹤0.01% 3365
2023
Q1 		$84K Buy
281
+12
+4% +$5.12K ﹤0.01% 4446
2022
Q4 		$92.4K Sell
269
-319
-54% -$77.1K ﹤0.01% 4505
2022
Q3 		$111K Buy
588
+169
+40% +$39.2K ﹤0.01% 4676
2022
Q2 		$88K Sell
419
-444
-51% -$93.4K ﹤0.01% 5097
2022
Q1 		$289K Buy
863
+63
+8% +$18.3K ﹤0.01% 4408
2021
Q4 		$260K Sell
800
-463
-37% -$199K ﹤0.01% 4808
2021
Q3 		$613K Buy
1,263
+94
+8% +$41.3K ﹤0.01% 3968
2021
Q2 		$543K Buy
1,169
+138
+13% +$75.2K ﹤0.01% 4126
2021
Q1 		$712K Buy
1,031
+12
+1% +$9.65K ﹤0.01% 3631
2020
Q4 		$753K Sell
1,019
-581
-36% -$453K ﹤0.01% 2903
2020
Q3 		$1.11M Buy
1,600
+194
+14% +$146K ﹤0.01% 2092
2020
Q2 		$1.19M Sell
1,406
-2,019
-59% -$1.32M 0.01% 1874
2020
Q1 		$1.23M Buy
+3,425
New +$1.23M 0.01% 1374

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Group One Trading's BTAI Position: Q1 2026 in Review

Group One Trading reduced its BioXcel Therapeutics (BTAI) stake by 100% in Q1 2026, selling an estimated $5.24K and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #7488.

Group One Trading first reported a position in BTAI in Q1 2020 and has held it in 20 quarters since. The position peaked at $1.3M in Q2 2020. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Group One Trading held 1 share of BioXcel Therapeutics worth $1 as of Q1 2026.
  • Group One Trading sold 3,184 BioXcel Therapeutics shares in Q1 2026, an estimated $5.24K.
  • BioXcel Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7488 holding.
  • Group One Trading first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 20 quarters since.
  • Group One Trading's BioXcel Therapeutics position peaked at $1.3M in Q2 2020.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.